

Zika Virus Infection - Pipeline Insight, 2021

<https://marketpublishers.com/r/ZD04BCD8A316EN.html>

Date: October 2021

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: ZD04BCD8A316EN

Abstracts

This report can be delivered to the clients within 48 hours

DelveInsight's, "Zika Virus Infection - Pipeline Insight, 2021," report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in Zika Virus Infection pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Zika Virus Infection Understanding

Zika Virus Infection: Overview

Zika fever is a mosquito-borne viral disease caused by Zika virus (ZIKV), consisting of mild fever, rash (mostly maculo-papular), headaches, arthralgia, myalgia, asthenia, and non-purulent conjunctivitis, occurring about two to seven days after the mosquito vector bite. Zika is spread mostly by the bite of an infected *Aedes* species mosquito (*Ae. aegypti* and *Ae. albopictus*). The symptoms typically last for 2-7 days. The diagnosis of the virus is done through a blood test. Zika virus infection during pregnancy can cause infants to be born with microcephaly and other congenital malformations, known as congenital Zika syndrome. Infection with Zika virus is also associated with other complications of pregnancy including preterm birth and miscarriage. Treatment consists of relieving pain, fever, and any other symptom that inconveniences the patient. To

prevent dehydration, it is recommended to control the fever, rest, and drink plenty of water.

'Zika Virus Infection - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Zika Virus Infection pipeline landscape is provided which includes the disease overview and Zika Virus Infection treatment guidelines. The assessment part of the report embraces, in depth Zika Virus Infection commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Zika Virus Infection collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Zika Virus Infection R&D. The therapies under development are focused on novel approaches to treat/improve Zika Virus Infection.

Zika Virus Infection Emerging Drugs Chapters

This segment of the Zika Virus Infection report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Zika Virus Infection Emerging Drugs

mRNA-1893: Moderna Therapeutics

mRNA-1893 contains an mRNA sequence encoding for the structural proteins of the Zika virus and is designed to cause cells to secrete virus-like particles, mimicking the response of the cell after natural infection. The drug is in Phase II clinical studies for the treatment of Zika Virus Infection. In August 2019, Moderna announced that the US FDA has granted Fast Track designation for its investigational Zika vaccine (mRNA-1893) for

the prevention of Zika virus infection in healthy adults.

GLS-5700: GeneOne Life Science

GLS-5700 is a DNA vaccine encoding the pre-membrane and envelop (prM-E) proteins of Zika virus (ZIKV). It is being developed by Geneone life science for Zika Virus Infection and is currently in Phase I stage of development.

Further product details are provided in the report.....

Zika Virus Infection: Therapeutic Assessment

This segment of the report provides insights about the different Zika Virus Infection drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Zika Virus Infection

There are approx. 12+ key companies which are developing the therapies for Zika Virus Infection. The companies which have their Zika Virus Infection drug candidates in the most advanced stage, i.e. Phase II include, Moderna Therapeutics.

Phases

DelveInsight's report covers around 12+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Zika Virus Infection pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Parenteral

Intravitreal

Subretinal

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Zika Virus Infection: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Zika Virus Infection therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Zika Virus Infection drugs.

Zika Virus Infection Report Insights

- Zika Virus Infection Pipeline Analysis

- Therapeutic Assessment

- Unmet Needs

- Impact of Drugs

Zika Virus Infection Report Assessment

- Pipeline Product Profiles

- Therapeutic Assessment

- Pipeline Assessment

- Inactive drugs assessment

- Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Zika Virus Infection drugs?

How many Zika Virus Infection drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Zika Virus Infection?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Zika Virus Infection therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Zika Virus Infection and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Moderna Therapeutics

GeneOne Life Science

WuXi Biologics

Inovio Pharmaceuticals

Takeda

Emergex Vaccines

Rigel Pharmaceuticals

Ala Wai Pharma Australia

Immunomodulation

Greffex

Biotron

Key Products

mRNA 1893

GLS-5700

Tyzivumab

INO-A002

TAK 426

EMX 001

Bemcentinib

Niclosamide

Annexin A5

Research programme: DNA vaccines

BIT 009

Contents

- Introduction
- Executive Summary
- Zika Virus Infection: Overview
 - Causes
 - Mechanism of Action
 - Signs and Symptoms
 - Diagnosis
 - Disease Management
- Pipeline Therapeutics
 - Comparative Analysis
- Therapeutic Assessment
 - Assessment by Product Type
 - Assessment by Stage and Product Type
 - Assessment by Route of Administration
 - Assessment by Stage and Route of Administration
 - Assessment by Molecule Type
 - Assessment by Stage and Molecule Type
- Zika Virus Infection – DelveInsight's Analytical Perspective
- Late Stage Products (Phase III)
 - Comparative Analysis
- Drug name: Company name
 - Product Description
 - Research and Development
 - Product Development Activities
- Drug profiles in the detailed report
- Mid Stage Products (Phase II)
 - Comparative Analysis
- mRNA 1893: Moderna Therapeutics
 - Product Description
 - Research and Development
 - Product Development Activities
- Drug profiles in the detailed report
- Early Stage Products (Phase I)
 - Comparative Analysis
- Tyzivumab: Tychan/WuXi Biologics
 - Product Description
 - Research and Development

Product Development Activities
Drug profiles in the detailed report
Preclinical and Discovery Stage Products
 Comparative Analysis
EMX 001: Emergex Vaccines
 Product Description
 Research and Development
 Product Development Activities
Drug profiles in the detailed report
Inactive Products
 Comparative Analysis
Zika Virus Infection Key Companies
Zika Virus Infection Key Products
Zika Virus Infection- Unmet Needs
Zika Virus Infection- Market Drivers and Barriers
Zika Virus Infection- Future Perspectives and Conclusion
Zika Virus Infection Analyst Views
Appendix

List Of Tables

LIST OF TABLES

Table 1 Total Products for Zika Virus Infection

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

- Figure 1 Total Products for Zika Virus Infection
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products

I would like to order

Product name: Zika Virus Infection - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/ZD04BCD8A316EN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/ZD04BCD8A316EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970